Black Diamond Therapeutics: Results From Phase 1 Dose Escalation Trial of Bdtx-1535 in GBM Patients Demonstrated Favorable Safety and Tolerability
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.